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steroid-refractory cases. Conclusion: ICIAC is a severe irAE which frequently requires high-dose steroids
and a close follow-up due to deleterious complications. The detection of histologically diagnosed deep
ulcerations may predict a steroid-refractory course and may warrant early application of infliximab.
However, larger studies are required to confirm our findings.
DOI: https://doi.org/10.1159/000507579






The following work is licensed under a Creative Commons: Attribution-NonCommercial 4.0 International
(CC BY-NC 4.0) License.
Originally published at:
Burla, Julian; Bluemel, Sena; Biedermann, Luc; Barysch, Marjam J; Dummer, Reinhard; Levesque,
Mitchell P; Gubler, Christoph; Morell, Bernhard; Rogler, Gerhard; Scharl, Michael (2020). Retrospective
Analysis of Treatment and Complications of Immune Checkpoint Inhibitor-Associated Colitis: Histolog-





Inflamm Intest Dis 2020;5:109–116
Retrospective Analysis of Treatment and 
Complications of Immune Checkpoint  
Inhibitor-Associated Colitis: Histological 
Ulcerations as Potential Predictor for a  
Steroid-Refractory Disease Course
Julian Burla a    Sena Bluemel a    Luc Biedermann a    Marjam J. Barysch b    
Reinhard Dummer b    Mitchell P. Levesque b    Christoph Gubler a    
Bernhard Morell a    Gerhard Rogler a    Michael Scharl a
aDivision of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; 
bDepartment of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
Received: February 4, 2020
Accepted: March 26, 2020
Published online: May 26, 2020
Prof. Dr. med. Michael Scharl
Department of Gastroenterology and Hepatology
University Hospital Zurich, Rämistrasse 100
CH–8091 Zurich (Switzerland)
michael.scharl@usz.ch
© 2020 The Author(s).





Malignant melanoma · Histology · Infliximab ·  
Vedolizumab · Nivolumab
Abstract
Background/Aims: Among the severe immune-related ad-
verse events (irAEs) that occur with immune checkpoint in-
hibitor (ICI) therapy, colitis is the most frequent one. This 
study aimed at describing the experience from the largest 
gastroenterology unit in Switzerland with immune check-
point inhibitor-associated colitis (ICIAC), its clinical presenta-
tion, management, and outcomes. Methods: We performed 
a retrospective review of patients who were referred for the 
evaluation of ICIAC between January 2011 and October 2018 
to the Division of Gastroenterology and Hepatology, Univer-
sity Hospital Zurich. Results: Thirty-three patients with im-
mune-related colitis grade 3 or 4 met the inclusion criteria 
and were analyzed in detail: All patients had diarrhea, 64% 
had abdominal pain, 42% had bloody stool, 27% had emesis, 
and 18% developed fever. In total, 33% were successfully 
treated with corticosteroids alone; 66% were steroid-refrac-
tory and treated with infliximab or vedolizumab. Two of 
these patients developed severe complications requiring 
surgery. All patients reached complete remission of ICIAC 
and its symptoms. At colonoscopy, ulcerations were seen in 
37% of steroid-refractory versus 63% of steroid-responsive 
cases. Deep histological ulcerations invading the submuco-
sa were only present in steroid-refractory cases. Conclusion: 
ICIAC is a severe irAE which frequently requires high-dose 
steroids and a close follow-up due to deleterious complica-
tions. The detection of histologically diagnosed deep ulcer-
ations may predict a steroid-refractory course and may war-
rant early application of infliximab. However, larger studies 
are required to confirm our findings. 
© 2020 The Author(s).
Published by S. Karger AG, Basel
Introduction
Checkpoint inhibitor molecules, such as ipilimumab, 
nivolumab, and pembrolizumab, are a successful new ap-
proach in cancer therapy. These antibodies block inhibi-
tory receptor proteins on the surface of T lymphocytes, 
This is an Open Access article licensed under the Creative Commons 
Attribution-NonCommercial-4.0 International License (CC BY-NC) 
(http://www.karger.com/Services/OpenAccessLicense), applicable to 
the online version of the article only. Usage and distribution for com-
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which are, otherwise, stimulated by cancer cells to obtain 
immune tolerance [1]. As a result, these drugs activate the 
immune system and trigger an immunogenic response 
against multiple malignancies with melanoma represent-
ing the best evaluated indication [2, 3]. Available antibod-
ies target CTLA-4 (cytotoxic T lymphocyte antigen 4), 
PD-1 (programmed cell death receptor-1), or PD-1 li-
gand 1 (PD-L1) [1–3]. Ipilimumab (anti-CTLA-4) is used 
for the treatment of melanoma, while pembrolizumab, 
nivolumab (both anti-PD-1), and atezolizumab (anti-
PD-L1) are additionally used in renal cell carcinoma, 
non-small cell lung cancer, urothelial cancer, and some 
other tumor types [4–9].
Nevertheless, checkpoint blockade may also lead to a 
loss of immune tolerance of healthy tissue [2]. This may 
result in a variety of side effects, referred to as immune-
related adverse events (irAEs). Besides skin rash, colitis is 
the most frequent irAE [10]. Overall, 15–25% of patients 
on single immunotherapy and about 65% of patients on 
combined immunotherapy suffer from grade 3 or grade 
4 irAEs [11, 12]. Up to 22% of patients on ipilimumab 
monotherapy and about 25% of patients on combined 
therapy suffer from severe (grade 3 or 4) enterocolitis that 
requires treatment interruption as well as high-dose ste-
roids and/or anti-TNF antibodies (infliximab) or even 
colectomy [12]. In general, most cases are mild to moder-
ate and respond to corticosteroids [13].
In this retrospective single-center analysis, we summa-
rize our experiences with immune checkpoint inhibitor-




We performed a retrospective review of patient charts from 
patients who were treated with ipilimumab alone or in combina-
tion with pembrolizumab or nivolumab and were referred to the 
Division of Gastroenterology and Hepatology, University Hospital 
Zurich, for the diagnostic evaluation of diarrhea between January 
2011 and October 2018. We included cases who (1) developed 
ICIAC, (2) were diagnosed with melanoma, and (3) had received 
one or more cycles of ICI at the Department of Dermatology at 
University Hospital Zurich. ICIAC is defined as colitis due to ICI 
therapy excluding other causes of bowel inflammation and diar-
rhea. Checkpoint inhibitor doses and courses were chosen accord-
ing to the standardized treatment regime approved by the Swiss 
health authorities. In case of drug toxicity, disease progression or 
death treatment was not completed.
Patient Data
All patients’ histories were profoundly assessed. We collected 
demographic and clinical data including sex, age, tumor stage ac-
cording to the American Joint Committee on Cancer (AJCC), type 
of therapy with checkpoint inhibitors, treatment courses, colitis 
and its symptoms, other associated irAEs, laboratory results, stool 
examinations, endoscopic findings, and histology reports of con-
ducted biopsies. For tumor staging (with prognostic relevance), 
the AJCC guidelines classify melanomas according to invasion 
depth into the following stages: <2.0 mm having no melanoma ul-
ceration (stage I), >1.0–2.0 mm with ulceration and >2.0–4.0 mm 
without ulceration (stage IIA), >2.0–4.0 mm with ulceration and 
>4.0 mm without ulceration (stage IIB), >4.0 mm with ulceration 
(stage IIC), any tumor depth with micrometastases/lymph node 
metastases or in-transit metastases (stage III), and any tumor 
depth with distant metastases (stage IV). Details can be found here 
[14]. Colitis was treated according to the current guidelines [15]. 
Patients were grouped into steroid-responsive patients, who re-
ceived only prednisone with or without budesonide to achieve 
complete remission, and steroid-refractory cases. We defined ste-
roid-refractory as colitis requiring treatment escalation with inf-
liximab, vedolizumab, or surgery.
The severity of diarrhea and colitis was graded according to the 
Common Terminology Criteria for Adverse Events (CTCAE), ver-
sion 4.03. Grade 1 diarrhea is defined as less than 4 bowel move-
ments per day over baseline, grade 2 as 4–6 bowel movements, 
grade 3 as 7 or more bowel movements, and grade 4 as life-threat-
ening consequences, with urgent intervention indicated. Grade 1 
colitis is asymptomatic (diagnostic observations only); grade 2 is 
associated with blood or mucus in the stool; grade 3 is defined as a 
change of bowel habits or severe abdominal pain; grade 4 indicates 
life-threatening consequences, for example, colonic perforations; 
and grade 5 represents death. Patients’ endoscopy reports includ-
ing image documentation were reviewed to analyze the distribution 
and characteristics of colitis. We defined “extensive colitis” as en-
doscopically detected inflammation on both sides of the colon 
(right colon: cecum and ascending colon; left colon: descending 
and sigmoid colon). Ulcerative colitis (macroscopic ulcers of any 
size or quantity) was separated from non-ulcerative inflammation. 
The histological diagnosis of an ulceration is defined as a lesion ex-
tending beyond the muscularis mucosae into the submucosa [16].
Data Presentation
Descriptive data are summarized as a number with percentage 
for nominal or median with range for continuous variables, re-
spectively. Analyses were performed with the SPSS software pack-
age, version 25 (IBM Corp., Armonk, NY, USA). Due to the small 
sample size, a statistical comparison between patients with differ-
ent colitis stages and/or a steroid refractory/responsive course 
does not appear to be valid and was therefore not performed.
Results
We identified 49 patients who were treated with ipili-
mumab alone or in combination with pembrolizumab or 
nivolumab and were referred to the Division of Gastro-
enterology and Hepatology, University Hospital Zurich, 
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Switzerland, for diagnostic evaluation of diarrhea. We fi-
nally included 33 patients who matched the inclusion cri-
teria (Fig. 1). Thirty patients underwent microbiological 
stool testing. An infectious cause of colitis was ruled out 
in 97%. One patient tested positive for Clostridium diffi-
cile toxin and was treated with metronidazole. After per-
sistence of symptoms despite antibiotic treatment, the pa-
tient was diagnosed with checkpoint inhibitor-induced 
colitis and needed additional treatment with corticoste-
roids and infliximab to recover.
Tumor Stage and Checkpoint Inhibitor Therapy
Detailed information about tumor stage and treatment 
is given in Table 1. All included patients with melanoma 
AJCC stage III or IV [14] developed immune-related coli-
tis and diarrhea. Most were treated with ipilimumab 
alone. About one-third additionally received pembroli-
zumab or nivolumab. Twenty-five patients were evalu-
ated according to the response evaluation criteria in solid 
tumors (RECIST): The majority had a progression of 
their melanoma, despite checkpoint inhibitor treatment 
(Table 1). Eight patients’ melanomas were treated in an 
adjuvant setting after complete resection (or radiation) 
and could not be evaluated by the RECIST due to lack of 
tumor lesions.
Clinical Presentation
Clinical features of the patients according to colitis 
grade are given in Table 2. Of the 33 included patients 
with colitis, 25 received a complete colonoscopy and an-
other 2 patients received a flexible sigmoidoscopy up to 
the left colonic flexure. Details on endoscopic findings are 
presented in Table 3, and representative endoscopic im-
49 patients assessed for eligibility
11 steroid-responsive 22 steroid-refractory
Complete remission




 7 without colitis
 5 colitis with other aetiology
 4 with other cancer-type
33 patients included
 27 colitis grade 3
   6 colitis grade 4
Table 1. Tumor stage and checkpoint inhibitor treatment
n (%)
Total number of patients 33 (100)




Cancer stagea III 11 (33)
Cancer stagea IV 22 (67)
Checkpoint inhibitor
Ipilimumab 19 (58)
Ipilimumab + pembrolizumab 2 (6)




Progressive disease 18/25 (72)
Partial response 3/25 (12)
Stable disease 0/25 (0)
Complete response 4/25 (16)
Data are presented as number (%), unless otherwise stated. 
a American Joint Committee on Cancer (AJCC). Tumor stages are 
given in the Methods section. b Response evaluation criteria in sol-
id tumors (RECIST).
Fig. 1. Flow chart of study inclusion and 
outcome.
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ages are shown in Figure 2. Two patients did not show 
visible signs of colitis: histopathological analysis of 1 pa-
tient confirmed inflammation, while in the other patient, 
modest lymphocytic infiltrates in conjunction with ele-
vated fecal calprotectin was found to confirm the diagno-
sis of colitis. Histological features present in colitis con-
sisted of immune cell infiltration, cryptitis, crypt abscess-
es, apoptosis, and ulcerations.
Patients with colitis grade 4 had significantly higher 
CRP and lower albumin values (Table 2). There was no 
difference between the endoscopic extents of inflamma-
tion. However, it appeared that grade 4 colitis patients 
slightly more often developed a steroid-refractory disease 
course (Table 3).





Total number of patients 27 (100) 6 (100)
Median (range) days between immune therapy initiation and symptom onset 50 (5–339) 30 (5–68)
≥3 symptomsa 7 (26) 5 (83)
CRP,b mg/L, median (range) at first presentation 14 (0.4–246) 108 (36–333)
Albumin, g/L, median (range) at first presentation 38.5 (30–43) 32 (23–36)
Endoscopic findings
Ulceration 8/22 (36) 4/5 (80)
Extensive colitis, right and left colon 9/22 (40) 3/5 (60)
Ulcers present in histology 5/22 (23) 2/5 (40)
Treatment
Steroid-refractory 16 (59) 6 (100)
Data presented as n (%), unless otherwise stated. a Symptoms: diarrhea, bloody stool, abdominal pain, fever (>38.2 ° C), emesis, and 
peritoneal signs. b CRP, C-reactive protein.
a b
c d
Fig. 2. Representative colonoscopy find-
ings (classified by the endoscopist) in pa-
tients with ICIAC. a Mild erythema and 
small erosions. b Extensive colitis with su-
perficial clean-based ulcers. c Extensive 
colitis with deep ulcerations. d Moderate 
erosions, with histology showing deep ul-
ceration into the submucosa.
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Treatment of Colitis
Detailed clinical features of the patients according to 
steroid-responsive versus steroid-refractory cases are 
given in Table 3. The majority of patients (88%) had to 
be hospitalized for treatment. All patients received ste-
roids as first-line therapy. Twenty-seven patients initial-
ly received high-dose prednisone (>1 mg/kg body 
weight). The remaining 6 patients initially receiving a 
lower prednisone dose required a dose escalation. In 21 
patients, the checkpoint inhibitor was discontinued – 







Total number of patients 33 (100) 11 (100) 22 (100)
Colitis CTCAEa
Grade 3 27 (82) 11 (100) 16 (73)
Grade 4 6 (18) 0 (0) 6 (27)
Diarrhoea CTCAE
Grade 1 or 2 15 (45) 4 (36) 11 (50)
Grade 3 18 (55) 7 (64) 11 (50)
Further symptoms
Bloody stools 14 (42) 3 (27) 11 (50)
Abdominal pain 21 (64) 7 (64) 14 (64)
Peritoneal signs 2 (6) 0 (0) 2 (9)
Emesis 9 (27) 2 (18) 7 (32)
Fever, >38.2 ° C 6 (18) 0 (0) 6 (27)
<4 doses ICIb received at symptom onset 23 (70) 4 (36) 19 (86)
Laboratory results
CRP,c mg/L, median (range) at first presentation 17 (0.4–333) 18 (1.5–246) 16 (0.4–333)
Albumin, g/L, median (range) at first presentation 37 (23–43) 38.5 (33–43) 37 (23–43)
Albumin <30 g/L at first presentation 3/28 (11) 0/8 (0) 3/20 (15)
Initial stool test for enteric pathogens negative 29/30 (97) 9/9 (100) 20/21 (95)
Endoscopic findings
Non-ulcerative 15/27 (56) 3/8 (38) 12/19 (62)
Ulceration 12/27 (44) 5/8 (63) 7/19 (37)
Extensive colitis, i.e., right and left colon 14/25 (56) 4/8 (50) 10/17 (59)
Histological findings
Histology consistent with colitis 25/27 (93) 8/8 (100) 17/19 (89)
Ulceration present 7/27 (26) 0 (0) 7/19 (37)
Treatment characteristics
Hospitalization due to colitis 29 (88) 8 (73) 21 (95)
High-dose prednisoned, oral or intravenous 33 (100) 11 (100) 22 (100)
High-dose budesonidee 7 (21) 3 (27) 4 (18)
Total days with steroids, median (range) 64 (4–167) 63 (4–151) 69 (23–167)
Infliximabf 20 (61) 0 (0) 20 (91)
Vedolizumabg 1 (3) 0 (0) 1 (5)
Surgery 4 (12) 0 (0) 4 (18)
Discontinuation of checkpoint inhibitor 21 (64) 4 (36) 17 (77)
Complications
Colonic perforation 2 (6) 0 (0) 2 (9)
Ruptured appendicitis 1 (3) 0 (0) 1 (5)
Perianal abscess or fistula 2 (6) 0 (0) 2 (9)
Superimposed Clostridium difficile colitish 3 (9) 1 (9) 2 (9)
Bleeding resulting in anemia 3 (9) 0 (0) 3 (14)
Data presented as n (%), unless otherwise stated. a CTCAE, Common Terminology Criteria for Adverse Events. b ICI, immune check-
point inhibitor. c CRP, C-reactive protein. d High-dose prednisone: >1 mg/kg body weight. e High-dose budesonide: >9 mg. f 5 mg/kg 
body weight. g 2 × 300 mg IV. h All successfully treated with metronidazole.
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significantly more often in steroid-refractory cases. The 
remaining 12 patients had either already completed 
their 4 cycles of therapy or discontinued therapy due to 
cancer progression or a different irAE. Other than colitis 
and diarrhea, common irAEs were skin rash (42%), thy-
roiditis (18%), hypophysitis, and pancreatitis (each 
12%). Furthermore, less frequent irAEs such as hepati-
tis, pneumonia, myocarditis, and uveitis were observed 
(each ≤6%). In 8 patients on a combination regime (6 
with ipilimumab/nivolumab and 2 with ipilimumab/
pembrolizumab), only ipilimumab treatment was 
stopped. This was sufficient for symptom control in 
conjunction with the initiation of corticosteroids. Seven 
patients (21%) received high-dose budesonide (>9 mg, 
oral or rectal foam), of which 3 received budesonide in 
order to taper prednisone. The median duration of ste-
roid treatment was 64 days (Table 3). In the absence of 
symptom control (“steroid-refractory” cases), immuno-
suppressive treatment was intensified after a median of 
13 days. Fourteen patients received a single infusion of 
infliximab (6 patients received up to 3 infusions). Ve-
dolizumab was used to treat steroid-refractory colitis in 
1 patient, who additionally suffered from multiple my-
eloma. The decision was made after consultation with 
hematologists, who advised against the use of inflix-
imab. In addition, prednisone was tapered as slow as 
over 158 days in this patient.
Features of Steroid-Responsive versus Steroid-
Refractory Colitis
Most clinical, laboratory, and endoscopic findings did 
not differ between steroid-responsive and steroid-refrac-
tory patients (Table 3). In steroid-refractory cases, it ap-
peared that colitis more often occurred before completing 
4 cycles of checkpoint inhibitor therapy (Table 3). In ad-
dition, fever was more often reported, while abdominal 
pain, bloody stools and emesis were not different com-
pared to steroid-responsive cases (Table 3). Of note, none 
of the steroid-responsive patients had colitis grade 4, 
while 6 (27%) of steroid-refractory patients had grade 4 
colitis (5 received infliximab, 3 were colectomized, ref. 
Fig.  1). Of the steroid-refractory patients, 5 developed 
complications: 2 suffered from severe gastrointestinal 
hemorrhage requiring transfusion, one developed a fis-
tula, and 2 underwent surgery due to sigmoid perfora-
tion. A very low albumin of <30 g/L was only seen in ste-
roid-refractory patients (Table 3).
Histologically detected ulcerations, which infiltrated 
deep into the submucosa, were only present in steroid-
refractory patients and were also detected in the afore-
mentioned colectomy specimens. Six of the 7 patients 
with histologically diagnosed ulcerations also had macro-
scopic findings described as ulcers by the endoscopist. In 
1 case, moderate erosions without macroscopic ulcerative 
inflammation were described at endoscopy (ref. Fig. 2d). 
However, histological analysis of biopsies revealed an ul-
cerative colitis with lesions extending beyond the muscu-
laris mucosae, thus being in agreement with the defini-
tion of histologic ulcerations.
Course of Melanoma Treatment
Regarding oncological response, the frequency of pa-
tients responding to the checkpoint inhibitor therapy 
(partial or complete) was higher in the steroid-refractory 
group (27 vs. 9%). The frequency of patients with tumor 
progression did not differ between steroid-responsive 
and -refractory cases (55% in both groups). Eight patients 
were treated with an anti-PD1 antibody (pembrolizum-
ab) following the treatment with ipilimumab. Of those, 1 
patient developed recurrent intestinal irAE (diarrhea 
grade III and colitis grade III). Another patient previous-
ly treated with ipilimumab received additional cycles of 
ipilimumab plus nivolumab and likewise developed re-
current colitis (diarrhea grade III and colitis grade II).
Discussion
In the present study, we analyzed clinical features, 
management, and outcomes of 33 melanoma patients 
suffering from severe checkpoint inhibitor-induced coli-
tis. Patients were treated with steroids in the first-line, 
followed by infliximab or vedolizumab in the second-
line. Consistent with more severe inflammation, patients 
with a CTCAE grade 4 colitis had higher CRP and lower 
albumin levels. Steroid-refractory cases had to discontin-
ue checkpoint inhibitors more often. In addition, histo-
logically diagnosed ulcerations were only present in ste-
roid-refractory patients.
All patients in our study presented with diarrhea. Ad-
ditional symptoms, such as bloody stools, emesis, fever, 
albumin <30 g/L, higher CTCAE colitis grade, and com-
plications, appeared to be more often in patients with a 
steroid-refractory course. In contrast to earlier studies, 
we did not detect endoscopic features connected to a ste-
roid-refractory disease course [16, 17]. Especially, macro-
scopically visible ulcerations were proposed to predict a 
steroid-refractory course [16, 18]. However, our findings 
did not confirm this. Of all analyzed patients, 63% of ste-
roid-responsive patients had ulcerations, while only 37% 
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of steroid-refractory patients had a colitis with macro-
scopically visible ulcers.
Of note, we detected an important histological differ-
ence between steroid-refractory and -responsive patients. 
Deep histologically present ulcerations invading the sub-
mucosa were only present in steroid-refractory cases. 
This was also detected in severe cases, leading to colec-
tomy. To the best of our knowledge, the predominance of 
such ulcerations in steroid-refractory cases has not been 
reported in earlier studies investigating checkpoint inhib-
itor-induced colitis. A recent study suggested a rapid 
colonoscopy (<7 days after colitis onset) because this de-
creases the overall duration of symptoms, steroid treat-
ment, and hospitalization rates [19]. In this context, our 
finding would further support early endoscopy in pa-
tients with grade 3 or 4 checkpoint inhibitor-induced 
colitis. Especially, if histological ulcerations are detected 
early, this could reduce the disease burden and complica-
tion rate by early steroid cessation and application of in-
fliximab or vedolizumab. In our study, we confirmed the 
prompt effect and good tolerability of infliximab for the 
treatment of checkpoint inhibitor-induced colitis. Twen-
ty patients were treated with infliximab, and 14 patients 
needed only one infliximab cycle (5 mg/kg). None of the 
patients developed side effects, and we did not observe an 
infliximab-resistant case. Infliximab resistance may be 
caused by cytomegalovirus (CMV) infection [20]. Seven-
teen of the 33 patients were evaluated for CMV by immu-
nohistochemistry, and all were negative (data not shown).
Recent literature shows no evidence indicating that the 
immunosuppressive treatment for colitis does attenuate 
the anti-neoplastic efficacy of ICI treatment [21, 22]. 
Most patients need only one dose of infliximab, and early 
administration could facilitate fast steroid tapering. Dur-
ing our follow-up (i.e., until complete remission of 
ICIAC), we did not see a worse tumor response in our 
steroid-refractory cohort. However, the influence of anti-
TNFα biologics on the efficacy of ICI therapy has to be 
evaluated in larger prospective trials with longer follow-
up comparing survival outcomes.
The presence of irAEs with checkpoint inhibitor ther-
apy has been identified as a positive prognostic factor for 
the probability of tumor response, because irAEs might 
serve as a surrogate for immune system activation by 
checkpoint inhibitor therapy [23, 24]. In line with this, we 
observed a better tumor response (partial or complete) in 
the steroid-refractory group (27 vs. 9%). In the steroid-
responsive group, we detected a resolution of colitis with 
cessation of ipilimumab. These 8 patients instead re-
ceived pembrolizumab. This is in line with the literature, 
showing a higher incidence of colitis with anti-CTLA-4 
therapy than anti-PD1 antibodies [10, 11, 25].
Our study included only patients who were treated in 
the Department of Gastroenterology and Hepatology. 
Our results may therefore be biased toward more severe 
cases, as mild cases of irAEs are usually treated by derma-
tologists themselves. This might explain the reported se-
verity of symptoms, high CTCAE grades, and the preva-
lence of complications, as a comparable recent study de-
tected a need for surgery in 3/60 patients (vs. 2/33 patients 
in our study) [26]. Furthermore, it also explains why such 
a high number of 22 patients (67%) presented with a ste-
roid-refractory disease course needed additional treat-
ment with infliximab or even surgery. And it might also 
explain why the majority of patients had cancer progres-
sion despite severe colitis, which is in contrast to an ear-
lier study investigating the disease course in patients with 
checkpoint inhibitor-induced colitis [26].
Checkpoint inhibitor therapy has evolved as a main-
stay in the treatment of multiple cancer indications with-
in the past few years. With its growing application, the 
incidence of irAEs such as diarrhea and colitis has in-
creased as well, and gastroenterologists are more likely to 
encounter such toxicities. We demonstrated that ICIAC 
can lead to severe complications, more often seen in ste-
roid-refractory patients. Therefore, factors predictive for 
a steroid-refractory disease course are important to be 
identified. As histologically detected deep ulcerations 
were only present in steroid-refractory patients, such ul-
cerations could aid identifying patients for a failure of ste-
roid-treatment. Prompt endoscopy leading to early inf-
liximab initiation and corticosteroid cessation might 
shorten symptoms and accelerate colitis resolution. How-
ever, this needs to be validated in larger and/or prospec-
tive studies.
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